Status:
RECRUITING
Blood Pressure Effects on Cognition and Brain Blood Flow in PD
Lead Sponsor:
University of California, San Diego
Collaborating Sponsors:
Beth Israel Deaconess Medical Center
Drexel University
Conditions:
Parkinson Disease
Orthostatic Hypotension
Eligibility:
All Genders
50+ years
Phase:
NA
Brief Summary
Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide. Besides causing symptoms that impair movement, PD also causes non-motor symptoms, such as problems thinking and...
Detailed Description
After reviewing and signing an IRB-approved informed consent, participants will undergo the following clinical assessments for the Screening Visit (duration 3 hours), to determine eligibility: 1. com...
Eligibility Criteria
Inclusion
- Diagnosis of idiopathic Parkinson Disease using the Movement Disorders Society (MDS) Clinical Diagnostic Criteria
- Age at least 50 years old
- Hoehn \& Yahr (H\&Y) stages I-III (early to moderate-stage PD; able to walk without assistance
- Proficiency in the English language (native English speaker level)
Exclusion
- Any involuntary movements (i.e., tremor or dyskinesia) \> 3 cm in amplitude (ok if movements are treated with medication), since the motion artifact could interfere with blood pressure monitor data collection
- Dementia (including PD dementia)
- History of deep brain stimulation (DBS) surgery
- Any current unstable, active medical problem, e.g. decompensated heart failure, liver failure, pneumonia, etc.
- Moderate or severe carotid artery stenosis (according to North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria
- History of cerebral infarction or hemorrhage
- Uncontrolled diabetes or any other systemic disease causing autonomic failure
- Syncope (fainting) within the past week
- Illiteracy (unable to read)
- Taking antihypertensive medications or alpha-adrenergic blocking medications, since these can cause hypotension (see \* below)
- Impairment of hearing or vision that is not corrected by devices (e.g., hearing aids or glasses)
- Currently pregnant (will be confirmed by women of child-bearing potential with a urine pregnancy test)
- Any other condition, which, in the opinion of the investigator, could place the participant at increased risk.
- Please note that persons may not participate if they are taking any of the following:
- medications to treat high blood pressure (called "antihypertensives") such as clonidine (Catapres), hydralazine, verapamil, diltiazem (Cartia), or medications ending in "-olol", "-artan", or "-pril")
- diuretics (also called "water pills") such as furosemide (Lasix), bumetanide (Bumex), hydrochlorothiazide (HCTZ; Microzide), or spironolactone (Aldactone)
- medications for enlarged prostate such as prazosin (Minipress), terazosin, doxazosin (Cardura), alfuzosin (Uroxatral), or tamsulosin (Flomax)
- If persons are taking these medications and would like to participate in the study, they will be advised to discuss whether they may discontinue these medications for 48 hours before the study visit with their prescribing doctor.
Key Trial Info
Start Date :
December 14 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05400174
Start Date
December 14 2021
End Date
February 1 2026
Last Update
August 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California San Diego
San Diego, California, United States, 92093